Clinical trials: sponsored by iOMEDICO AG
Cholangiocarcinoma
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment option for this disease.
- Trial name
- IDHIRA (NCT06607302)
- Where
- 19 sites in Germany
- Volunteers
- 100 people
- Sponsor
- iOMEDICO AG
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
- Conditions
- Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III
- Trial name
- CRISP (NCT02622581)
- Testing
- data collection
- Where
- Germany
- Volunteers
- 14,500 people
- Sponsor
- AIO-Studien-gGmbH
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world…
- Conditions
- Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Trial name
- ARIADNE (NCT05326308)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 845 people
- Sponsor
- iOMEDICO AG
Metastatic Colorectal Cancer (mCRC)
Fruquintinib in Patients With Metastatic Colorectal Cancer
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard…
- Trial name
- FRUQUENT (NCT06787105)
- Where
- 42 sites in Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Liver Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- JADE (NCT04510740)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iOMEDICO AG
Renal Cell Carcinoma, Urothelial Carcinoma
Registry Platform Urologic Cancer
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- CARAT (NCT03374267)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,230 people
- Sponsor
- iOMEDICO AG
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL)
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- RUBIN (NCT06043011)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,950 people
- Sponsor
- iOMEDICO AG
Colorectal Cancer Metastatic
Registry Platform Colorectal Cancer
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic colorectal cancer, treated in palliative intention in daily routine practice in Germany.
- Trial name
- AZURITE (NCT04867525)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Myeloma Registry Platform (MYRIAM)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- MYRIAM (NCT03308474)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,200 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable.
- Trial name
- MARINA (NCT07559799)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- iOMEDICO AG
Breast Cancer
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and…
- Trial name
- ELENI (NCT07563595)
- Testing
- Elacestrant, Standard of care (Investigator Choice)
- Where
- 3 sites in Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Breast Cancer
Breast Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- OPAL (NCT03417115)
- Where
- Germany
- Volunteers
- 6,150 people
- Sponsor
- iOMEDICO AG
Primary Myelofibrosis, Secondary Myelofibrosis
Research Platform Myelofibrosis and Anemia
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- RHODOLITE (NCT06976918)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- iOMEDICO AG
CLL
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
The goal of CICERO is to investigate the clinical outcome with a particular focus on prospective data on safety using acalabrutinib (+/- obinutuzumab) in CLL patients receiving co-medication with DOACs (edoxaban, rivaroxaban…
- Trial name
- CICERO (NCT05517265)
- Testing
- Calquence
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- iOMEDICO AG
Acute Myeloid Leukemia (AML)
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC
The goal of this non-interventional study is to evaluate quality of life (QoL) in adult patients with newly diagnosed IDH1 R132-mutated AML who are not eligible to receive standard induction chemotherapy and who are treated with…
- Trial name
- CONFIDHENCE (NCT06181734)
- Testing
- Ivosidenib
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- iOMEDICO AG
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- SAPHIR (NCT04290806)
- Testing
- Routine care as per site standard
- Where
- Germany
- Volunteers
- 1,900 people
- Sponsor
- iOMEDICO AG
Ovarian Cancer, Endometrial Cancer
Registry Platform Ovarian and Endometrial Cancer
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm, Endometrial Neoplasms
- Trial name
- SMARAGD (NCT05129969)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,975 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine.
- Trial name
- SEATTLE (NCT05954780)
- Testing
- Selinexor
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- iOMEDICO AG
Polycythemia Vera
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting.
- Trial name
- ROPE (NCT06743035)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- iOMEDICO AG
Glioma
Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma
The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population.
- Trial name
- VIOLETA (NCT07240662)
- Testing
- Vorasidenib
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG